Vismodegib in basal cell carcinoma

Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, describes a recent multicenter real-world evidence study on the use of vismodegib, a hedgehog pathway inhibitor, in treating advanced basal cell carcinoma (BCC). Retrospective analysis of data from 108 patients with locally advanced or metastatic BCC demonstrated that treatment with vismodegib resulted in a median progression free survival (PFS) rate of over 30 months, a two year PFS rate of over 60% and only 5% of patients reporting grade 3 and 4 adverse events. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.